Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 866 clinical trials
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

etoposide
lung neoplasm
chemoradiation therapy
adjuvant therapy
stage iv nsclc
  • 0 views
  • 19 Feb, 2024
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

The purpose of this trial is to find out if the addition of pembrolizumab to usual chemotherapy is better or worse than usual chemotherapy alone for non-small cell lung cancer.

squamous non-small cell lung carcinoma
squamous cell carcinoma of lung
immunohistochemistry
sarcoma
lung non-small cell squamous carcinoma
  • 0 views
  • 19 Feb, 2024
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progressive free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

pulmonary metastasis
squamous non-small cell lung cancer
immune checkpoint inhibitor
non-squamous non-small cell lung cancer
squamous nsclc (non-small cell lung cancer)
  • 0 views
  • 19 Feb, 2024
  • 169 locations
Randomised Evaluation of COVID-19 Therapy

RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma or Tocilizumab prevents death in patients with COVID-19.

acute respiratory syndrome (sars)
colchicine
iv immunoglobulin
ritonavir
corticosteroids
  • 0 views
  • 19 Feb, 2024
Giessen Pulmonary Hypertension in Lung Cancer Registry

The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity …

  • 0 views
  • 19 Feb, 2024
Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19)

The aim of this study is to evaluate the lung ultrasound in Covid19 ARDS.

SARS
acute respiratory syndrome (sars)
acute respiratory distress
respiratory distress
lung disease
  • 0 views
  • 19 Feb, 2024
Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC

Immunotherapy for PD-L1 positive patients is still ineffective in some patientswhich may be related to the complex immune microenvironment.In view of this bottleneck, further refinement of immunotyping and in-depth study of drug resistance mechanism are the most important tasks. In this observational study, we evaluated the difference of gene mutation …

small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Evaluation of Clinical Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)

The aim of this study is the characterization from epidemiological, radiomics and molecular point of view of lung metastasis of patients at beginning affected by pancreatic adenocarcinoma (PDAC), which after the resection of primitive tumor have met with initial recurrence of the disease exclusively at the lung level.

adenocarcinoma
primary tumor
pdac
pancreatic adenocarcinoma
metastasis
  • 0 views
  • 19 Feb, 2024
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = >3 months).

  • 0 views
  • 19 Feb, 2024
Point of Care Ultrasound to Evaluate Diaphragmatic Function in Children Undergoing Thoracic Surgery

In addition, we examine if there is a relationship between diaphragmatic dysfunction and pulmonary complications, including postoperative lung atelectasis.

  • 0 views
  • 19 Feb, 2024